OncoMatch/Clinical Trials/NCT07197554
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Is NCT07197554 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ST-01156 for advanced solid tumors.
Treatment: ST-01156 — A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Sarcoma
Hepatocellular Carcinoma
Cholangiocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: rbm39 inhibitor/degrader
Lab requirements
Blood counts
adequate organ function as defined in the protocol
Kidney function
adequate organ function as defined in the protocol
Liver function
adequate organ function as defined in the protocol
Has adequate organ function as defined in the protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The City of Hope National Medical Center · Duarte, California
- Hoag Memorial Hospital · Newport Beach, California
- Mass General Brigham Cancer Institute · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07197554 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior rbm39 inhibitor/degrader disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages